Biopharmaceutical News and Research

RSS

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research 101st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

13 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

NeoStem opens new adult stem cell collection center in Austin, TX

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010.

13 Apr 2010

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.

13 Apr 2010

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

12 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

CoreLab Partners' new logo and brand identity launched

CoreLab Partners, Inc, the recently established global entity resulting from the merger between RadPharm and Medifacts International, has launched a new brand identity to reinforce their capabilities as one of the largest imaging sciences and cardiac safety core labs in the market today.

12 Apr 2010

BioClinica to showcase expanded suite of services at upcoming global industry conferences

BioClinica, Inc., a leading provider of clinical trial management services will participate in, and present at, key industry conferences during April and May. Principal members of the BioClinica team will participate as expert panelists as well as demonstrate the value of the Company's expanded suite of services at these conferences.

From Clario 12 Apr 2010

PAREXEL International experts to present key industry topics during conference in Orlando

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will present key industry topics during the 19th Annual Partnerships in Clinical Trials Conference, to be held April 12 – 14, 2010 in Orlando, Florida.

From Parexel 9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Apr 2010

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC.

8 Apr 2010

Debiopharm Group, Biocartis sign investment agreement

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.

8 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

BeaconEquity.com releases investment report on Cell Therapeutics

BeaconEquity.com announces an investment report featuring biotech company Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

7 Apr 2010

StockPreacher.com: GenVec's revenues for 2009 decline by 8%

StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

Achaogen announces completion of $56M Series C round of financing

Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was led by new investor Frazier Healthcare Ventures, and also included new investor Alta Partners.

7 Apr 2010

TD2 to join GPEC at BayBio2010 to spur Arizona's bioscience industry

Scottsdale-based TGen Drug Development will join the Greater Phoenix Economic Council this week at BayBio2010 in an effort to spur Arizona's bioscience industry.

7 Apr 2010

Biopharmaceutical News and Research

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

Investment report on Rexahn Pharmaceuticals

NeoStem opens new adult stem cell collection center in Austin, TX

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CoreLab Partners' new logo and brand identity launched

BioClinica to showcase expanded suite of services at upcoming global industry conferences

PAREXEL International experts to present key industry topics during conference in Orlando

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Debiopharm Group, Biocartis sign investment agreement

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

BeaconEquity.com releases investment report on Cell Therapeutics

StockPreacher.com: GenVec's revenues for 2009 decline by 8%

Achaogen announces completion of $56M Series C round of financing

TD2 to join GPEC at BayBio2010 to spur Arizona's bioscience industry

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News